Cancer screening pioneer appointed first 'Emeritus Scientist' by Clinical Genomics

Monday Aug 10th 2015: Clinical Genomics is pleased to announce that Howard Chandler has been appointed as the inaugural 'Emeritus Scientist' for Clinical Genomics. Mr Chandler is a pioneer in the field of clinical diagnostics and the inventor and developer of the patient-friendly "brush" form of faecal immunochemical test (FIT) for bowel cancer screening. His technology revolutionalised bowel cancer screening and is currently used to test millions of people in the US and Australia.

Mr Chandler is in effect returning to the company he co-founded as Enterix in 1997. The company was then taken over by Clinical Genomics in October 2013. As 'Emeritus Scientist' Mr Chandler will play a leading role in the development of future technology and products.

Dr. Lawrence LaPointe, CEO says Clinical Genomics will benefit greatly from Mr Chandler's new appointment.

"Howard has a long standing history in the field of medical diagnostics. His talent to invent incredibly simple solutions to save lives and to make medical decisions easier has benefited millions of people around the world. More recently his work in colorectal cancer screening and monitoring kicked off the wave of modern tests we now see used in screening programs," Dr LaPointe says. "He will play an important role in shaping our product offerings in the future."

Mr. Chandler has over thirty-six issued patents and is the author of numerous scientific publications. In the 1970s he invented the world's first rapid immunoassay test to diagnose the species of snake venom following a bite.

Mr Chandler is pleased to be back on board at Clinical Genomics.

"The development of the original test was a significant advance in the screening of colorectal cancer," said Mr Chandler. "Coming back into the company as it is expanding internationally and having further success with their ground-breaking blood test for colorectal cancer is very exciting."

A range of companies have marketed products based upon Mr Chandler's patents such as Abbott Laboratories, Alere, Beckman-Coulter Primary Care Diagnostics, Becton Dickinson, Binax, CSL, Glaxo Welcome, AMRAD-ICT, Agen Biomedical, Synbiotics, and Quest Diagnostics. Mr. Chandler holds an M.Agr.Sc degree and Diploma of Education from the University of Melbourne (Australia).

This appointment follows a year of international expansion for Clinical Genomics, most recently in the Asia Pacific region with the announcement of new deals in New Zealand and The Philippines.

###